A non-invasive, easy-to-use test, like the Cologuard test, is a simple and effective way to screen for colorectal cancer. In ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer ...

That’s why timely screening should be part of your regular health check-upPurdue University’s Center for Healthy Living (CHL), in conjunction with Cologuard® and Exact Sciences, is providing no-cost, ...

Exact Sciences stock collapsed Wednesday — undercutting its 50-day and 200-day lines — after the Cologuard maker reported ...

2 The partnership also highlights the Cologuard ® test as an effective, non-invasive tool to help improve screening rates for adults 45 and older who are eligible. The stool-based Cologuard test ...

With the anticipated launch of Cologuard Plus in the second quarter of 2025, the price increase is projected to contribute positively to the company’s revenue growth, adding approximately 400 ...

Cologuard Plus secures 16% pricing rises from Centers for Medicare & Medicaid Services. Exact Sciences is also likely to renegotiate commercial contracts for higher pricing, which may gradually ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Included was a final decision related to CMS pricing for Exact Sciences Corp’s (NASDAQ:EXAS) Cologuard Plus, a second-generation test that received FDA approval in October. William Blair writes ...

Sure. Well -- so the price here is for Cologuard Plus, which is a tremendous new innovation. It's a test that delivers -- detects 95% of cancers at a 94% specificity, that specificity is ...

This approach contributed to strong growth in Cologuard test utilization among rescreen patients and within care gap programs during the third quarter. Exact Sciences received FDA approval for the ...